MiMedx Group Inc (MDXG)vsVertex Pharmaceuticals Inc (VRTX)
MDXG
MiMedx Group Inc
$3.95
+1.28%
HEALTHCARE · Cap: $646.49M
VRTX
Vertex Pharmaceuticals Inc
$529.69
+1.66%
HEALTHCARE · Cap: $126.66B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 3444% more annual revenue ($12.59B vs $355.17M). VRTX leads profitability with a 35.0% profit margin vs 1.8%. VRTX appears more attractively valued with a PEG of 1.90. VRTX earns a higher WallStSmart Score of 64/100 (C+).
MDXG
Hold43
out of 100
Grade: D
VRTX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+87.4%
Fair Value
$41.37
Current Price
$3.95
$37.42 discount
Margin of Safety
+45.0%
Fair Value
$952.30
Current Price
$529.69
$422.61 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 99.5% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
Smaller company, higher risk/reward
ROE of 2.9% — below average capital efficiency
1.8% margin — thin
Weak financial health signals
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MDXG
The strongest argument for MDXG centers on EPS Growth, Debt/Equity, Altman Z-Score.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : MDXG
The primary concerns for MDXG are Market Cap, Return on Equity, Profit Margin. A P/E of 110.8x leaves little room for execution misses. Thin 1.8% margins leave little buffer for downturns.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
MDXG profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
MDXG carries more volatility with a beta of 1.17 — expect wider price swings.
VRTX is growing revenue faster at 12.5% — sustainability is the question.
VRTX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (64/100 vs 43/100), backed by strong 35.0% margins and 12.5% revenue growth. MDXG offers better value entry with a 87.4% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
MiMedx Group Inc
HEALTHCARE · BIOTECHNOLOGY · USA
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company is headquartered in Marietta, Georgia.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?